Investor Presentaiton slide image

Investor Presentaiton

Accelerating commercial progress Mar- Jul 22 31 Aug 22 30 Sep 22 19 Oct 22 4DMedical™ 25 Oct 22 Making significant progress across all areas of operations Major success as Vanderbilt 'burn pit' trial hits primary endpoint Continuing engagement with legislators, advocates and the VA 4DMedical progress towards full reimbursement in the U.S. 4DMedical release of CT LVASTM in Australia • XV Scanner unveiled at Prince of Wales Hospital in Sydney. • . US clinical pilot at Providence St Joseph commenced. Johns Hopkins COPD clinical trial results presented at ATS. Three-year national contract • signed with I-MED. • XV TechnologyⓇ validated through US clinical trials. • Facilitates commercial prospects in the US. • Supports significant opportunities with the already built VA and DoD relationships. Increase research benefiting veterans exposed to burn pits and toxic air. Collaborating with advocates, including Rosie Torres of Burn Pits 360. Enabling the PACT Act to reach its full potential, by scaling up VA evaluation and diagnosis processes without an invasive biopsy. AMA accepts XV LVASⓇ application to establish a new CPT code. Cat III code is a milestone for XV LVASⓇ to become a fully commercialised reimbursable product in the U.S. Expands 4DMedical's product visibility in the broader U.S. payer space. Strong news flow pipeline across all areas of operations • 4DMedical releases Computed Tomography Lung Ventilation Analysis Software (CT LVAS™). Expands patient accessibility by leveraging readily available CT hardware. Seamless integration enabled through the existing I-MED partnership. 4DMedical Limited | Investor Presentation | November 2022 3
View entire presentation